|

TAD After Chemotherapy in Locally Advanced Breast Cancer

RECRUITINGSponsored by Hospital Universitari de Bellvitge
Actively Recruiting
SponsorHospital Universitari de Bellvitge
Started2021-02-01
Est. completion2026-06-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05763641

Summary

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Axillary lymph node metastasis proven by cytology
* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
* Neoadjuvant chemotherapy

Exclusion Criteria:

* cN3 verified by imaging tests
* N2 due to internal mammary involvement (N2b).
* Tumors whose surrogate molecular subtype is luminal A.
* Patients undergoing neoadjuvant endocrine therapy
* Patients with local recurrences and metastatic tumors.

Conditions4

Breast CancerCancerLocally AdvancedSentinel Lymph Node

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.